PMID- 37293508 OWN - NLM STAT- MEDLINE DCOM- 20230612 LR - 20240426 IS - 1664-2392 (Print) IS - 1664-2392 (Electronic) IS - 1664-2392 (Linking) VI - 14 DP - 2023 TI - The oxidative aging model integrated various risk factors in type 2 diabetes mellitus at system level. PG - 1196293 LID - 10.3389/fendo.2023.1196293 [doi] LID - 1196293 AB - BACKGROUND: Type 2 diabetes mellitus (T2DM) is a chronic endocrine metabolic disease caused by insulin dysregulation. Studies have shown that aging-related oxidative stress (as "oxidative aging") play a critical role in the onset and progression of T2DM, by leading to an energy metabolism imbalance. However, the precise mechanisms through which oxidative aging lead to T2DM are yet to be fully comprehended. Thus, it is urgent to integrate the underlying mechanisms between oxidative aging and T2DM, where meaningful prediction models based on relative profiles are needed. METHODS: First, machine learning was used to build the aging model and disease model. Next, an integrated oxidative aging model was employed to identify crucial oxidative aging risk factors. Finally, a series of bioinformatic analyses (including network, enrichment, sensitivity, and pan-cancer analyses) were used to explore potential mechanisms underlying oxidative aging and T2DM. RESULTS: The study revealed a close relationship between oxidative aging and T2DM. Our results indicate that nutritional metabolism, inflammation response, mitochondrial function, and protein homeostasis are key factors involved in the interplay between oxidative aging and T2DM, even indicating key indices across different cancer types. Therefore, various risk factors in T2DM were integrated, and the theories of oxi-inflamm-aging and cellular senescence were also confirmed. CONCLUSION: In sum, our study successfully integrated the underlying mechanisms linking oxidative aging and T2DM through a series of computational methodologies. CI - Copyright (c) 2023 Chen, Yao, Zhao, Xu, Ren, Xie, Liu and Wang. FAU - Chen, Yao AU - Chen Y AD - Department of Biomedical Engineering, School of Intelligent Medicine, China Medical University, Shenyang, Liaoning, China. FAU - Yao, Lilin AU - Yao L AD - Department of Biomedical Engineering, School of Intelligent Medicine, China Medical University, Shenyang, Liaoning, China. FAU - Zhao, Shuheng AU - Zhao S AD - Department of Biomedical Engineering, School of Intelligent Medicine, China Medical University, Shenyang, Liaoning, China. FAU - Xu, Mengchu AU - Xu M AD - Department of Biomedical Engineering, School of Intelligent Medicine, China Medical University, Shenyang, Liaoning, China. FAU - Ren, Siwei AU - Ren S AD - Department of Biomedical Engineering, School of Intelligent Medicine, China Medical University, Shenyang, Liaoning, China. FAU - Xie, Lu AU - Xie L AD - Shanghai-MOST Key Laboratory of Health and Disease Genomics & Institute for Genome and Bioinformatics, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai, China. FAU - Liu, Lei AU - Liu L AD - Intelligent Medicine Institute, Fudan University, Shanghai, China. FAU - Wang, Yin AU - Wang Y AD - Department of Biomedical Engineering, School of Intelligent Medicine, China Medical University, Shenyang, Liaoning, China. AD - Key Laboratory of GI Cancer Etiology and Prevention in Liaoning Province, The First Hospital of China Medical University, Shenyang, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230524 PL - Switzerland TA - Front Endocrinol (Lausanne) JT - Frontiers in endocrinology JID - 101555782 SB - IM EIN - Front Endocrinol (Lausanne). 2024 Apr 03;15:1363078. PMID: 38633758 MH - Humans MH - *Diabetes Mellitus, Type 2/etiology/metabolism MH - Aging/metabolism MH - Risk Factors MH - Oxidative Stress MH - Oxidation-Reduction PMC - PMC10244788 OTO - NOTNLM OT - aging OT - energy metabolism OT - oxidative stress OT - pan-cancer analysis OT - type 2 diabetes mellitus COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/06/09 06:42 MHDA- 2023/06/12 06:42 PMCR- 2023/01/01 CRDT- 2023/06/09 04:36 PHST- 2023/03/29 00:00 [received] PHST- 2023/05/10 00:00 [accepted] PHST- 2023/06/12 06:42 [medline] PHST- 2023/06/09 06:42 [pubmed] PHST- 2023/06/09 04:36 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - 10.3389/fendo.2023.1196293 [doi] PST - epublish SO - Front Endocrinol (Lausanne). 2023 May 24;14:1196293. doi: 10.3389/fendo.2023.1196293. eCollection 2023.